Shots:

• The ongoing P-III trial involves assessing REGEN-COV (casirivimab & imdevimab) in 2000+ participants used as a passive vaccine to prevent COVID-19. An exploratory analysis- conducted on the first ~400 individuals- randomized to receive passive vaccination with REGEN-COV (1200mg- SC) vs PBO
• Reduction in overall infections seen within 1st week with 100% prevention of symptomatic infections- 50% lower overall rates of infection and decreased peak virus levels and duration of viral shedding in asymptomatic infections
• The confirmatory P-III results are expected early in Q2’21. REGEN-COV is being studied in two hospitalized patient trials and a P-III study for non-hospitalized patients

 ­ Ref: PRNewswire | Image: Regeneron